Aardvark Therapeutics (NASDAQ:AARD) Price Target Raised to $26.00 at Bank of America

Aardvark Therapeutics (NASDAQ:AARD) had its target price upped by stock analysts at Bank of America from $22.00 to $26.00 in a research note issued on Thursday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price target suggests a potential upside of 235.92% from the stock’s current price.

A number of other equities research analysts also recently commented on the company. Morgan Stanley assumed coverage on Aardvark Therapeutics in a research report on Monday, March 10th. They issued an “overweight” rating and a $29.00 price objective for the company. Cantor Fitzgerald assumed coverage on Aardvark Therapeutics in a report on Monday, March 10th. They issued an “overweight” rating and a $50.00 price target for the company. Finally, Royal Bank of Canada initiated coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They set an “outperform” rating and a $21.00 price objective on the stock.

Aardvark Therapeutics Trading Down 13.0 %

AARD stock opened at $7.74 on Thursday. Aardvark Therapeutics has a one year low of $7.74 and a one year high of $19.58.

Insider Activity at Aardvark Therapeutics

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 16,542 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $16.00 per share, with a total value of $264,672.00. Following the purchase, the chief executive officer now owns 1,496,175 shares in the company, valued at approximately $23,938,800. The trade was a 1.12 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Nelson Sun purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $160,000.00. Following the completion of the transaction, the chief financial officer now owns 99,484 shares in the company, valued at $1,591,744. This trade represents a 11.18 % increase in their position. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.